Ian E Krop1, Seock-Ah Im2, Carlos Barrios3, Hervé Bonnefoi4, Julie Gralow5, Masakazu Toi6, Paul A Ellis7, Luca Gianni8, Sandra M Swain9, Young-Hyuck Im10, Michelino De Laurentiis11, Zbigniew Nowecki12, Chiun-Sheng Huang13, Louis Fehrenbacher14, Yoshinori Ito15, Jigna Shah16, Thomas Boulet17, Haiying Liu16, Harrison Macharia17, Peter Trask16, Chunyan Song16, Eric P Winer1, Nadia Harbeck18. 1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. 2. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 3. Oncology Research Unit, Oncoclínicas, HSL, PUCRS, Porto Alegre, Brazil. 4. Institut Bergonié Unicancer and Bordeaux University, Bordeaux, France. 5. University of Washington, Seattle, WA. 6. Graduate School of Medicine, Kyoto University, Kyoto, Japan. 7. Guy's Hospital and Sarah Cannon Research Institute, London, UK. 8. Michelangelo Foundation, Milan, Italy. 9. Georgetown University Medical Center and MedStar Health, Washington, DC. 10. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 11. IRCCS Instituto Nazionale Tumori Fondazione Pascale, Naples, Italy. 12. Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 13. National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 14. Kaiser Permanente, Northern California, Vallejo, CA. 15. Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. 16. Genentech, Inc, South San Francisco, CA. 17. F. Hoffmann-La Roche, Basel, Switzerland. 18. Breast Center, Dept. OB&GYN, LMU University Hospital, Munich, Germany.
Abstract
PURPOSE: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS: The phase III KAITLIN study (NCT01966471) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor-negative, and tumor > 2.0 cm). Postsurgery, patients were randomly assigned 1:1 to anthracycline-based chemotherapy (three-four cycles) and then 18 cycles of T-DM1 plus pertuzumab (AC-KP) or taxane (three-four cycles) plus trastuzumab plus pertuzumab (AC-THP). Adjuvant radiotherapy/endocrine therapy was permitted. Coprimary end points were invasive disease-free survival (IDFS) in the intention-to-treat node-positive and overall populations with hierarchical testing. RESULTS: The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) for AC-THP (n = 918) and 57.0 months (interquartile range, 52.1-59.8 months) for AC-KP (n = 928). There was no significant IDFS difference between arms in the node-positive (n = 1,658; stratified hazard ratio [HR], 0.97; 95% CI, 0.71 to 1.32) or overall population (n = 1846; stratified HR, 0.98; 95% CI, 0.72 to 1.32). In the overall population, the three-year IDFS was 94.2% (95% CI, 92.7 to 95.8) for AC-THP and 93.1% (95% CI, 91.4 to 94.7) for AC-KP. Treatment completion rates (ie, 18 cycles) were 88.4% for AC-THP and 65.0% for AC-KP (difference driven by T-DM1 discontinuation because of laboratory abnormalities [12.5%]). Similar rates of grade ≥ 3 (55.4% v 51.8%) and serious adverse events (23.3% v 21.4%) occurred with AC-THP and AC-KP, respectively. KP decreased clinically meaningful deterioration in global health status versus THP (stratified HR, 0.71; 95% CI, 0.62 to 0.80). CONCLUSION: The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
PURPOSE: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS: The phase III KAITLIN study (NCT01966471) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor-negative, and tumor > 2.0 cm). Postsurgery, patients were randomly assigned 1:1 to anthracycline-based chemotherapy (three-four cycles) and then 18 cycles of T-DM1 plus pertuzumab (AC-KP) or taxane (three-four cycles) plus trastuzumab plus pertuzumab (AC-THP). Adjuvant radiotherapy/endocrine therapy was permitted. Coprimary end points were invasive disease-free survival (IDFS) in the intention-to-treat node-positive and overall populations with hierarchical testing. RESULTS: The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) for AC-THP (n = 918) and 57.0 months (interquartile range, 52.1-59.8 months) for AC-KP (n = 928). There was no significant IDFS difference between arms in the node-positive (n = 1,658; stratified hazard ratio [HR], 0.97; 95% CI, 0.71 to 1.32) or overall population (n = 1846; stratified HR, 0.98; 95% CI, 0.72 to 1.32). In the overall population, the three-year IDFS was 94.2% (95% CI, 92.7 to 95.8) for AC-THP and 93.1% (95% CI, 91.4 to 94.7) for AC-KP. Treatment completion rates (ie, 18 cycles) were 88.4% for AC-THP and 65.0% for AC-KP (difference driven by T-DM1 discontinuation because of laboratory abnormalities [12.5%]). Similar rates of grade ≥ 3 (55.4% v 51.8%) and serious adverse events (23.3% v 21.4%) occurred with AC-THP and AC-KP, respectively. KP decreased clinically meaningful deterioration in global health status versus THP (stratified HR, 0.71; 95% CI, 0.62 to 0.80). CONCLUSION: The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
Authors: Kim Cocks; Madeleine T King; Galina Velikova; Marrissa Martyn St-James; Peter M Fayers; Julia M Brown Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Ian E Krop; Sung-Bae Kim; Antonio González-Martín; Patricia M LoRusso; Jean-Marc Ferrero; Melanie Smitt; Ron Yu; Abraham C F Leung; Hans Wildiers Journal: Lancet Oncol Date: 2014-05-02 Impact factor: 41.316
Authors: Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga Journal: N Engl J Med Date: 2017-06-05 Impact factor: 91.245
Authors: Edith A Perez; Carlos Barrios; Wolfgang Eiermann; Masakazu Toi; Young-Hyuck Im; Pierfranco Conte; Miguel Martin; Tadeusz Pienkowski; Xavier B Pivot; Howard A Burris; Jennifer A Petersen; Sanne De Haas; Silke Hoersch; Monika Patre; Paul Anthony Ellis Journal: Cancer Date: 2019-07-18 Impact factor: 6.860
Authors: A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés Journal: Ann Oncol Date: 2013-05-22 Impact factor: 32.976
Authors: Melina L Willson; Lucinda Burke; Thomas Ferguson; Davina Ghersi; Anna K Nowak; Nicholas Wilcken Journal: Cochrane Database Syst Rev Date: 2019-09-02
Authors: Edith A Perez; Carlos Barrios; Wolfgang Eiermann; Masakazu Toi; Young-Hyuck Im; Pierfranco Conte; Miguel Martin; Tadeusz Pienkowski; Xavier Pivot; Howard Burris; Jennifer A Petersen; Sven Stanzel; Alexander Strasak; Monika Patre; Paul Ellis Journal: J Clin Oncol Date: 2016-11-07 Impact factor: 44.544
Authors: Sara A Hurvitz; Miguel Martin; Kyung Hae Jung; Chiun-Sheng Huang; Nadia Harbeck; Vicente Valero; Daniil Stroyakovskiy; Hans Wildiers; Mario Campone; Jean-François Boileau; Peter A Fasching; Karen Afenjar; Gonzalo Spera; Vanesa Lopez-Valverde; Chunyan Song; Peter Trask; Thomas Boulet; Joseph A Sparano; W Fraser Symmans; Alastair M Thompson; Dennis Slamon Journal: J Clin Oncol Date: 2019-06-03 Impact factor: 44.544
Authors: Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski Journal: Cancer Res Date: 2008-11-15 Impact factor: 13.312
Authors: Coralia Bueno Muiño; Miguel Martín; María Del Monte-Millán; José Ángel García-Saénz; Sara López-Tarruella Journal: Cancers (Basel) Date: 2022-01-20 Impact factor: 6.639